Vimseltinib
Vimseltinib (DCC-3014) is a c-FMS (CSF-IR) and c-Kit dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has IC50s of [1]. Vimseltinib has certain oral bioavailability[2].
Product Specifications
CAS Number
1628606-05-2
Product Name Alternative
DCC-3014
UNSPSC
12352005
Hazard Statement
H315, H319
Target
C-Fms; c-Kit
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/c-kit-in-5.html
Purity
99.94
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1N(C)C(NC(C)C)=NC=C1C2=NC(C)=C(OC3=CC(C4=CN(C)N=C4)=NC=C3)C=C2
Molecular Formula
C23H25N7O2
Molecular Weight
431.49
Precautions
H315, H319
References & Citations
[1]Yumi Ahn, et al. 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities. WO2014145025A2.|[2]Kisielewska K, et al. An evaluation of vimseltinib for treatment of tenosynovial giant cell tumors. Expert Rev Anticancer Ther. 2025 Apr;25 (4) :327-335.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
